Literature DB >> 9846983

Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells.

H W Sohn1, E Y Choi, S H Kim, I S Lee, D H Chung, U A Sung, D H Hwang, S S Cho, B H Jun, J J Jang, J G Chi, S H Park.   

Abstract

Programmed cell death (PCD) is a prominent feature of the development of the immune and nervous systems. In both systems, widespread PCD occurs in primitive progenitor cells during development. In this study, we demonstrated that Ewing's sarcoma (ES) cells, undifferentiated neural precursors, underwent apoptosis upon engagement of CD99 with anti-CD99 monoclonal antibody. Apoptosis via CD99 occurred only in the undifferentiated state of ES cells, but not in differentiated ES cells. CD99-induced apoptosis in ES cells appeared to require de novo synthesis of RNA and protein as well as caspase activation. Cyclosporin A, known to be a potent inhibitor of both calcineurin activation and mitochondrial permeability transition pore opening, inhibited CD99-mediated apoptosis, whereas FK-506, a specific calcineurin inhibitor, did not, indicating the induction of CD99-mediated apoptosis through a calcineurin-independent pathway. Furthermore, the dying cells displayed the reduction of mitochondrial transmembrane potential (delta psi m). These results suggest that CD99 engagement induce CsA-inhibitable mitochondrial permeability transition pore opening, followed by a reduction of delta psi m and caspase activation, thereby leading to apoptosis. Based on these results, we suggest the possible involvement of CD99 in the apoptotic processes that occur during nervous system development and also its application in immunotherapeutic trials for ES cases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9846983      PMCID: PMC1866321          DOI: 10.1016/S0002-9440(10)65707-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  Analysis of the membrane potential of rat- and mouse-liver mitochondria by flow cytometry and possible applications.

Authors:  P X Petit; J E O'Connor; D Grunwald; S C Brown
Journal:  Eur J Biochem       Date:  1990-12-12

2.  Ewing's sarcoma: new approaches to histogenesis and molecular plasticity.

Authors:  W J Rettig; P Garin-Chesa; A G Huvos
Journal:  Lab Invest       Date:  1992-02       Impact factor: 5.662

3.  Engagement of CD99 induces up-regulation of TCR and MHC class I and II molecules on the surface of human thymocytes.

Authors:  E Y Choi; W S Park; K C Jung; S H Kim; Y Y Kim; W J Lee; S H Park
Journal:  J Immunol       Date:  1998-07-15       Impact factor: 5.422

4.  Experimental evidence for a neural origin of Ewing's sarcoma of bone.

Authors:  A O Cavazzana; J S Miser; J Jefferson; T J Triche
Journal:  Am J Pathol       Date:  1987-06       Impact factor: 4.307

5.  Shrinkage necrosis: a distinct mode of cellular death.

Authors:  J F Kerr
Journal:  J Pathol       Date:  1971-09       Impact factor: 7.996

6.  Inhibition by cyclosporin A of a Ca2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress.

Authors:  M Crompton; H Ellinger; A Costi
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

7.  Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor.

Authors:  H Kovar; M Dworzak; S Strehl; E Schnell; I M Ambros; P F Ambros; H Gadner
Journal:  Oncogene       Date:  1990-07       Impact factor: 9.867

8.  Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2.

Authors:  E J Fellinger; P Garin-Chesa; T J Triche; A G Huvos; W J Rettig
Journal:  Am J Pathol       Date:  1991-08       Impact factor: 4.307

9.  The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product.

Authors:  C Gelin; F Aubrit; A Phalipon; B Raynal; S Cole; M Kaczorek; A Bernard
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

10.  Evidence for heterogeneous groups of neuronal differentiation of Ewing's sarcoma.

Authors:  S Hara; Y Adachi; Y Kaneko; J Fujimoto; J Hata
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

View more
  22 in total

1.  Expression of CD99 in pleomorphic carcinomas of the lung.

Authors:  Seong-Ho Yoo; Jungho Han; Tae Jin Kim; Doo Hyun Chung
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

2.  The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit.

Authors:  L Landuzzi; C De Giovanni; G Nicoletti; I Rossi; C Ricci; A Astolfi; L Scopece; K Scotlandi; M Serra; G P Bagnara; P Nanni; P L Lollini
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  CD99-Derived Agonist Ligands Inhibit Fibronectin-Induced Activation of β1 Integrin through the Protein Kinase A/SHP2/Extracellular Signal-Regulated Kinase/PTPN12/Focal Adhesion Kinase Signaling Pathway.

Authors:  Kyoung-Jin Lee; Yuri Kim; Yeon Ho Yoo; Min-Seo Kim; Sun-Hee Lee; Chang-Gyum Kim; Kyeonghan Park; Dooil Jeoung; Hansoo Lee; In Young Ko; Jang-Hee Hahn
Journal:  Mol Cell Biol       Date:  2017-06-29       Impact factor: 4.272

Review 4.  Recent advances in the molecular pathogenesis of Ewing's sarcoma.

Authors:  E C Toomey; J D Schiffman; S L Lessnick
Journal:  Oncogene       Date:  2010-06-14       Impact factor: 9.867

5.  Nuclear factor-κB2 represses Sp1-mediated transcription at the CD99 promoter.

Authors:  Eun Kyung Lee; Ji Hye Chae; Myung-Soo Kang
Journal:  Mol Cells       Date:  2011-10-19       Impact factor: 5.034

6.  CD99 acts as an oncosuppressor in osteosarcoma.

Authors:  Maria Cristina Manara; Ghislaine Bernard; Pier-Luigi Lollini; Patrizia Nanni; Monia Zuntini; Lorena Landuzzi; Stefania Benini; Giovanna Lattanzi; Marika Sciandra; Massimo Serra; Mario Paolo Colombo; Alain Bernard; Piero Picci; Katia Scotlandi
Journal:  Mol Biol Cell       Date:  2006-01-18       Impact factor: 4.138

Review 7.  Ewing tumour: incidence, prognosis and treatment options.

Authors:  M Paulussen; B Fröhlich; H Jürgens
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

8.  Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99.

Authors:  Haydar Çelik; Marika Sciandra; Bess Flashner; Elif Gelmez; Neslihan Kayraklıoğlu; David V Allegakoen; Jeff R Petro; Erin J Conn; Sarah Hour; Jenny Han; Lalehan Oktay; Purushottam B Tiwari; Mutlu Hayran; Brent T Harris; Maria Cristina Manara; Jeffrey A Toretsky; Katia Scotlandi; Aykut Üren
Journal:  Oncogene       Date:  2018-01-31       Impact factor: 9.867

9.  Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia.

Authors:  Vijaya Pooja Vaikari; Mincheol Park; Lena Keossayan; J Andrew MacKay; Houda Alachkar
Journal:  Nanomedicine       Date:  2020-06-12       Impact factor: 5.307

10.  Interaction of CD99 with its paralog CD99L2 positively regulates CD99L2 trafficking to cell surfaces.

Authors:  Giri Nam; Young-Kwan Lee; Hye Yeong Lee; Min Jung Ma; Masatake Araki; Kimi Araki; Seungbok Lee; Im-Soon Lee; Eun Young Choi
Journal:  J Immunol       Date:  2013-10-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.